FLT1 and breast carcinoma: In fact, AMF-26 can induce complete tumor regression in breast cancer xenografts [54], reduce the proliferation of 39 different cancers in a variety of human organs (such as breast, colon, kidney, skin, central nervous system, lung, ovary, and stomach) [53,55], as well as diminish angiogenesis through suppressing the activation of the vascular endothelial growth factor receptor 1/2 (VEGFR1/2) and the nuclear factor-κB (NF-κB) pathways [56].